oral contraception
Women's health · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals National Aboriginal Community Controlled Health Organisation |
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals National Aboriginal Community Controlled Health Organisation |
Who spoke
National Aboriginal Community Controlled Health Organisation
What the PBS pays
$7M in government benefit over 2024–25, across 369,093 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| drospirenone with ethinylestradiol | $7.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.